Please ensure Javascript is enabled for purposes of website accessibility

Why BioNTech Stock Is Jumping Again Today

By Keith Speights - May 5, 2021 at 12:44PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Health Canada authorized the company's COVID-19 vaccine for kids ages 12 to 15.

What happened

Shares of BioNTech (BNTX 1.36%) were jumping 9.2% higher as of 12:30 p.m. EDT on Wednesday. The gain came after Health Canada authorized the COVID-19 vaccine developed by BioNTech and Pfizer (PFE -0.87%) for children as young as 12 years old.

So what

The Pfizer-BioNTech COVID-19 vaccine was already available in Canada for individuals ages 16 and up. The new authorization for adolescents should help the country fight COVID-19 more effectively. Around one-fifth of all Canadian cases of COVID-19 have affected children and teens.

Healthcare professional giving a vaccine shot to a young boy

Image source: Getty Images.

Canada currently has agreements in place with Pfizer and BioNTech to supply up to 76 million doses this year. This supply deal is more than enough to fully vaccinate all of the country's residents in 2021.  The two drugmakers also reached an agreement with the Canadian government to supply up to 125 million doses of the vaccine in 2022 and 2023. Canada has options to buy up to 60 million doses in 2024 as well.

Now what

BioNTech and Pfizer seem likely to secure U.S. Emergency Use Authorization for their COVID-19 vaccine in kids ages 12 to 15 as early as next week. BioNTech is scheduled to report its first-quarter results on May 10, potentially providing another key catalyst for the biotech stock

Keith Speights owns shares of Pfizer. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioNTech SE Stock Quote
BioNTech SE
BNTX
$162.53 (1.36%) $2.19
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$49.67 (-0.87%) $0.43

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.